NFKB1 and cancer: Multiple reports have already demonstrated that NDRG2 expression in cancer cells is able to inhibit the NF-κB, MAPK, and STAT signaling pathways [11,21,22], thus raising the hypothesis that NDRG2 expression may hamper PD-L1 expression in tumor cells.